Ignasi CarriÃ³

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7724557/publications.pdf

Version: 2024-02-01

70	1,129	394421	414414
papers	citations	19 h-index	32 g-index

78	78	78	1770
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Digital PET vs Analog PET: Clinical Implications?. Seminars in Nuclear Medicine, 2022, 52, 302-311.	4.6	14
2	International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 895-904.	6.4	23
3	AMYQ: An index to standardize quantitative amyloid load across PET tracers. Alzheimer's and Dementia, 2021, 17, 1499-1508.	0.8	11
4	International consensus on the use of [18F]-FDG PET/CT in pediatric patients affected by epilepsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3827-3834.	6.4	13
5	Avances y nuevas indicaciones de la tomografÃa por emisiÃ³n de positrones. Medicina ClÃnica, 2021, 156, 65-67.	0.6	0
6	Liquid biopsies and molecular imaging: friends or foes?. Clinical and Translational Imaging, 2020, 8, 47-50.	2.1	3
7	Striking neurologic 18F-FDG PET/CT pattern in Devicâ€™s disease (neuromyelitis optica spectrum) Tj ETQq1 1 0.784314 rgBT /Overlo	6.4	4
8	Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. Journal of Nuclear Medicine, 2020, 61, 1278-1283.	5.0	51
9	Ernest V. Garcia, PhD (Born 1948). Journal of Nuclear Cardiology, 2020, 27, 1919-1922.	2.1	0
10	AmyQ: An index to accurately measure cerebral amyloid load. Alzheimer's and Dementia, 2020, 16, e039735.	0.8	0
11	Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 572-578.	6.4	24
12	A Conversation Between Ignasi CarriÃ³ and Ken Herrmann. Journal of Nuclear Medicine, 2020, 61, 638-640.	5.0	0
13	Future Challenges of Multimodality Imaging. Recent Results in Cancer Research, 2020, 216, 905-918.	1.8	1
14	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	3.7	44
15	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Physics, 2019, 6, 6.	2.7	0
16	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 8.	3.9	0
17	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Research, 2019, 9, 34.	2.5	0
18	Digital vs. analog PET/CT: intra-subject comparison of the SUVmax in target lesions and reference regions. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1745-1750.	6.4	43

#	Article	IF	Citations
19	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. European Journal of Hybrid Imaging, 2019, 3, 6.	1.5	0
20	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1399-1399.	6.4	2
21	Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters. Clinical Nuclear Medicine, 2019, 44, e1-e5.	1.3	11
22	Comparison of image quality and lesion detection between digital and analog PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1383-1390.	6.4	68
23	The impact of bilingualism on brain structure and function in Huntington's disease. Parkinsonism and Related Disorders, 2019, 60, 92-97.	2.2	22
24	Structural and metabolic brain correlates of apathy in Huntington's disease. Movement Disorders, 2018, 33, 1151-1159.	3.9	37
25	Striking lack of visualization of striatum on 18F-FDG brain PET in chorea-acanthocytosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 511-512.	6.4	1
26	Brain FDG-PET: clinical use in dementing neurodegenerative conditions. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1467-1469.	6.4	2
27	123I-mIBG and the phantom tollbooth. Journal of Nuclear Cardiology, 2018, 25, 1198-1200.	2.1	1
28	Does inflammation get on nerves in patients with heart failure?. Journal of Nuclear Cardiology, 2018, 25, 854-856.	2.1	0
29	Advancing EJNMMI: continuing success and next developments. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2029-2031.	6.4	0
30	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	10.7	90
31	Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk. Journal of Nuclear Cardiology, 2017, 24, 377-391.	2.1	46
32	The natural history of takotsubo syndrome: a two-year follow-up study with myocardial sympathetic and perfusion G-SPECT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 267-283.	6.4	13
33	Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1671-1678.	6.4	47
34	Saving costs in cancer patient management through molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2153-2157.	6.4	0
35	Response to 223Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report. Oncology Letters, 2016, 12, 1323-1328.	1.8	4
36	New section in EJNMMI and Annals of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2448-2448.	6.4	3

#	Article	IF	Citations
37	In Vivo Dynamic Metabolic Changes After Transplantation of Induced Pluripotent Stem Cells for Ischemic Injury. Journal of Nuclear Medicine, 2016, 57, 2012-2015.	5.0	6
38	New section in EJNMMI and Annals of Nuclear Medicine. Annals of Nuclear Medicine, 2016, 30, 593-593.	2.2	4
39	Striatal hypometabolism in premanifest and manifest Huntingtonâ€™s disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2183-2189.	6.4	32
40	Cardiac Innervation Imaging: Implications for Risk Stratification and Therapeutic Decision-Making. Current Cardiovascular Imaging Reports, 2016, 9, 1.	0.6	1
41	Molecular Image-Guided Theranostic and Personalized Medicine 2014. BioMed Research International, 2015, 2015, 1-2.	1.9	0
42	Recomendaciones para la utilizaciÃ³n de biomarcadores de imagen PET en el proceso diagnÃ³stico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.0	16
43	Why New Journals? The Growth of the EJNMMI Family. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1625-1626.	6.4	1
44	Molecular Image-Guided Theranostic and Personalized Medicine 2013. BioMed Research International, 2014, 2014, 1-2.	1.9	1
45	A computational framework for cancer response assessment based on oncological PET-CT scans. Computers in Biology and Medicine, 2014, 55, 92-99.	7.0	4
46	2013: another good year for EJNMMI. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1791-1793.	6.4	3
47	Controversies in amyloid-Î² imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 201-201.	6.4	1
48	Farewell to Anneliese Sand. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1815-1815.	6.4	0
49	Cardiac Sympathetic Imaging With mIBG in Heart Failure. JACC: Cardiovascular Imaging, 2010, 3, 92-100.	5.3	156
50	December editorâ€™s remarks. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1893-1896.	6.4	1
51	A note from the lighthouse. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1381-1383.	6.4	1
52	Best Practice in Nuclear Medicine 1. , 2006, , .		0
53	December 2005: Editorâ€™s remarks. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1351-1353.	6.4	0
54	Reflections after 1ï¿½year online. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1569-1571.	6.4	0

#	Article	IF	Citations
55	The EJNM, an integrative vehicle for information transfer in nuclear medicine and molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1-2.	6.4	0
56	Important developments for the European Journal of Nuclear Medicine and Molecular Imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1319-1319.	6.4	0
57	European Journal of Nuclear Medicine and Molecular Imaging manuscript processing goes online. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1320-1321.	6.4	0
58	Concordance between rest MIBG and exercise tetrofosmin defects: possible use of rest MIBG imaging as a marker of reversible ischaemia. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 614-619.	2.1	8
59	Burden of myocardial damage in cardiac allograft rejection: Scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. Journal of Nuclear Cardiology, 2000, 7, 132-139.	2.1	29
60	Myocardial sympathetic innervation in the athlete's sinus bradycardia: Is there selective inferior myocardial wall denervation?. Journal of Nuclear Cardiology, 2000, 7, 354-358.	2.1	22
61	Somatostatin receptor scintigraphy predicts impending cardiac allograft rejection before endomyocardial biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1754-1759.	2.1	17
62	Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischaemic heart disease. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 333-339.	6.4	17
63	The end of the â€œDecade of the Brainâ€: reflections on European nuclear neuroimaging and implications of the EANM congress. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 955-957.	2.1	2
64	Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1482-1488.	6.4	31
65	Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. Journal of Nuclear Cardiology, 1998, 5, 551-557.	2.1	50
66	Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 767-773.	2.1	30
67	Assessing anthracycline cardiotoxicity in the 1990s. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 359-364.	2.1	13
68	Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age1. Journal of Nuclear Cardiology, 1995, 2, 126-132.	2.1	49
69	Clinical future of antimyosin imaging in noncoronary heart disease. Journal of Nuclear Cardiology, 1995, 2, 155-158.	2.1	2
70	Technetium-99m human polyclonal immunoglobulin G studies and conventional bone scans to detect active joint inflammation in chronic rheumatoid arthritis. European Journal of Nuclear Medicine and Molecular Imaging, 1992, 19, 173-6.	2.1	42